Legal & General Group
ARTV

Legal & General Group’s Artiva Biotherapeutics ARTV Stock Holding History

Legal & General Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,018
Closed -$6.05K – 3574
2025
Q1 		$6.05K Buy
2,018
+625
+45% +$3.37K ﹤0.01% 3251
2024
Q4 		$14K Hold
1,393
– – ﹤0.01% 3160
2024
Q3 		$21.5K Buy
+1,393
New +$16.1K ﹤0.01% 3022

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Legal & General Group's ARTV Position: Q2 2025 in Review

Legal & General Group sold out of Artiva Biotherapeutics (ARTV) in Q2 2025, closing a stake of 2,018 shares — an estimated $6.05K sold.

Legal & General Group first reported a position in ARTV in Q3 2024 and held it in 3 quarters. The position peaked at $21.5K in Q3 2024. 48 funds tracked by Wall St. Rank hold ARTV as of Q2 2025.

  • Legal & General Group reported no remaining Artiva Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 2,018 Artiva Biotherapeutics shares in Q2 2025, an estimated $6.05K.
  • Legal & General Group first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 3 quarters.
  • Legal & General Group's Artiva Biotherapeutics position peaked at $21.5K in Q3 2024.
  • 48 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.